CytomX Therapeutics Profit Margin

As of the most recent data (June 2026), CTMX shows a profit margin of -435.21%. That compares with 34.01% in the prior-year period — down 1379.8% year over year. That is below the Healthcare sector average of 9.48%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CTMX's profit margin is now -435.21% (was 34.01%) — a 1379.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether CytomX Therapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 9.48%. CytomX Therapeutics is at -435.21%, which is lower that average. That is roughly 4690.4% below the sector mean. Use the comparison chart on this page to see how CTMX stacks up against individual peers as well.

That compares with 34.01% in the prior-year period — down 1379.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare CytomX Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has CytomX Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -435.21%) with ownership activity and broader fundamentals.